ATE203414T1 - Anthracycline konjugate, deren herstellung und deren verwendung als antitumorwirkstoffe - Google Patents

Anthracycline konjugate, deren herstellung und deren verwendung als antitumorwirkstoffe

Info

Publication number
ATE203414T1
ATE203414T1 AT94913560T AT94913560T ATE203414T1 AT E203414 T1 ATE203414 T1 AT E203414T1 AT 94913560 T AT94913560 T AT 94913560T AT 94913560 T AT94913560 T AT 94913560T AT E203414 T1 ATE203414 T1 AT E203414T1
Authority
AT
Austria
Prior art keywords
pct
mol
image
preparation
residue
Prior art date
Application number
AT94913560T
Other languages
German (de)
English (en)
Inventor
Francesco Angelucci
Maria Grandi
Antonino Suarato
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Application granted granted Critical
Publication of ATE203414T1 publication Critical patent/ATE203414T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Polyamides (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT94913560T 1993-05-11 1994-04-08 Anthracycline konjugate, deren herstellung und deren verwendung als antitumorwirkstoffe ATE203414T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939309663A GB9309663D0 (en) 1993-05-11 1993-05-11 Biologically active compounds
PCT/EP1994/001100 WO1994026311A1 (en) 1993-05-11 1994-04-08 Anthracycline conjugates, their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
ATE203414T1 true ATE203414T1 (de) 2001-08-15

Family

ID=10735264

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94913560T ATE203414T1 (de) 1993-05-11 1994-04-08 Anthracycline konjugate, deren herstellung und deren verwendung als antitumorwirkstoffe

Country Status (25)

Country Link
US (1) US5571785A (https=)
EP (1) EP0649312B1 (https=)
JP (1) JPH08502519A (https=)
KR (1) KR100330635B1 (https=)
CN (1) CN1098106C (https=)
AT (1) ATE203414T1 (https=)
AU (1) AU671741B2 (https=)
CA (1) CA2136438C (https=)
DE (1) DE69427799T2 (https=)
DK (1) DK0649312T3 (https=)
ES (1) ES2161764T3 (https=)
FI (1) FI112602B (https=)
GB (1) GB9309663D0 (https=)
GR (1) GR3036978T3 (https=)
HU (2) HUT70509A (https=)
IL (1) IL109528A (https=)
MY (1) MY110974A (https=)
NZ (1) NZ265266A (https=)
PL (1) PL175325B1 (https=)
PT (1) PT649312E (https=)
RU (1) RU2145965C1 (https=)
TW (1) TW268015B (https=)
UA (1) UA42695C2 (https=)
WO (1) WO1994026311A1 (https=)
ZA (1) ZA943212B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9721070D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
EP1401875A4 (en) * 2001-05-04 2005-01-26 Univ Utah Res Found HYALURONIC ACID-CONTAINING BIOKON JUGATES: TARGETED DELIVERY OF ANTIBODIES TO CANCER CELLS
WO2003037915A1 (en) * 2001-10-31 2003-05-08 Biopolymed Inc. Biocompatible polymers including peptide spacer
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
WO2005004805A2 (en) * 2003-07-02 2005-01-20 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
JP6744826B2 (ja) 2014-06-13 2020-08-19 バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC Ｆａｐ活性化治療剤及びそれに関連する使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
JPS60246400A (ja) * 1984-05-22 1985-12-06 Ajinomoto Co Inc アントラサイクリン系化合物及び制ガン剤
GB8614323D0 (en) * 1986-06-12 1986-07-16 Erba Farmitalia Anthracyclines
US5169937A (en) * 1986-11-18 1992-12-08 The Scripps Research Institute Method for producing stable glycosylated hemoglobin
DE3722699A1 (de) * 1987-07-09 1989-01-19 Behringwerke Ag Zytostatisch wirksame anthacyclin-konjugate
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
GB9026491D0 (en) * 1990-12-05 1991-01-23 Erba Carlo Spa Anthracycline-conjugates

Also Published As

Publication number Publication date
GB9309663D0 (en) 1993-06-23
FI946128A0 (fi) 1994-12-28
KR100330635B1 (ko) 2002-09-17
JPH08502519A (ja) 1996-03-19
EP0649312A1 (en) 1995-04-26
HUT70509A (en) 1995-10-30
CA2136438C (en) 2004-09-14
FI946128A7 (fi) 1994-12-28
NZ265266A (en) 1996-06-25
AU6566694A (en) 1994-12-12
MY110974A (en) 1999-07-31
US5571785A (en) 1996-11-05
UA42695C2 (uk) 2001-11-15
HU211538A9 (en) 1995-12-28
FI112602B (fi) 2003-12-31
CN1108454A (zh) 1995-09-13
EP0649312B1 (en) 2001-07-25
IL109528A (en) 1998-08-16
HU9403811D0 (en) 1995-03-28
RU2145965C1 (ru) 2000-02-27
AU671741B2 (en) 1996-09-05
CA2136438A1 (en) 1994-11-24
ZA943212B (en) 1995-01-18
PL175325B1 (pl) 1998-12-31
PT649312E (pt) 2002-01-30
PL306861A1 (en) 1995-04-18
TW268015B (https=) 1996-01-11
CN1098106C (zh) 2003-01-08
WO1994026311A1 (en) 1994-11-24
KR950702201A (ko) 1995-06-19
IL109528A0 (en) 1994-08-26
RU94046336A (ru) 1996-10-27
DE69427799T2 (de) 2002-05-02
DK0649312T3 (da) 2001-11-12
GR3036978T3 (en) 2002-01-31
ES2161764T3 (es) 2001-12-16
DE69427799D1 (de) 2001-08-30

Similar Documents

Publication Publication Date Title
DK0673258T3 (da) Polymerbundne camptothecinderivater
TW266201B (https=)
DE69412250D1 (de) Pyridobismidazole enthaltendes rigid-rod-Polymer
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
AU7585091A (en) Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it
BR9408246A (pt) Composto derivado de 3-azabicicloalcano N-substituído
NO952744L (no) Cytokinbegrensende midler
BRPI0107731B8 (pt) método para purificar daptomicina
CA2456620A1 (en) Compositions comprising photo-labile perfume delivery systems
ATE203414T1 (de) Anthracycline konjugate, deren herstellung und deren verwendung als antitumorwirkstoffe
DK0819132T3 (da) Fremgangsmåde til fremstilling af anthracyclin-antibiotika
ITTO930167A1 (it) Derivati dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso come farmaci potenzianti la memoria e l'apprendimento.
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
EE200200599A (et) Tsüklipostiiniühend kasutamiseks diabeedivastase ravimina, seda sisaldav farmatseutiline preparaat,ühendi ja preparaadi valmistamine ning selleks vajalik mikroorganism
HU901424D0 (en) Process for the preparation of thienyl-acetic acid derivatives and pharmaceutical compositions containing such compounds

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee